Workflow
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates
VXRTVaxart(VXRT) ZACKS·2025-03-20 22:15

Company Performance - VAXART, INC. reported a quarterly loss of 0.05pershare,betterthantheZacksConsensusEstimateofalossof0.05 per share, better than the Zacks Consensus Estimate of a loss of 0.10, and an improvement from a loss of 0.12pershareayearago,representinganearningssurpriseof500.12 per share a year ago, representing an earnings surprise of 50% [1] - The company posted revenues of 15.19 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 51.28%, compared to year-ago revenues of 3.25million[2]−Overthelastfourquarters,VAXARThassurpassedconsensusEPSestimatesthreetimes,buthastoppedconsensusrevenueestimatesonlyonce[2]StockPerformance−VAXARTshareshavedeclinedapproximately11.83.25 million [2] - Over the last four quarters, VAXART has surpassed consensus EPS estimates three times, but has topped consensus revenue estimates only once [2] Stock Performance - VAXART shares have declined approximately 11.8% since the beginning of the year, while the S&P 500 has decreased by 3.5% [3] - The current consensus EPS estimate for the upcoming quarter is -0.16 on revenues of 12.39million,andforthecurrentfiscalyear,itis−12.39 million, and for the current fiscal year, it is -0.44 on revenues of $58.5 million [7] Industry Outlook - The Medical - Drugs industry, to which VAXART belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact VAXART's stock performance [5]